![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks
|
|
|
Reported by Jules Levin
CROI 2011 Feb 27-March 2 Boston
Anthony Mills,1 Andrea Antinori,2 Bonaventura Clotet,3 Martin Fisher,4 Jan Fourie,5 Gisela Herrera,6 Charles Hicks,7 Jose Valdez Madruga,8 Simon Vanveggel,9 Marita Stevens9
1Anthony Mills MD Inc., Los Angeles, CA, USA; 2National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS, Rome, Italy; 3Hospital Universitari Germans Trias i Pujol and irsiCaixa Foundation, UAB, Barcelona, Spain;4HIV/GUM Research Department, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; 5Dr J Fourie Medical Centre, Dundee, KwaZulu Natal, South Africa; 6Hospital CIMA San Jose, San Jose, Costa Rica;7Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA; 8Centro de Referncia e Treinamento DST/AIDS, Mariana-So Paulo, Brazil; 9Tibotec BVBA, Beerse, Belgium
![apasl1.gif](../images/031211/031211-2/apasl1.gif)
![apasl2.gif](../images/031211/031211-2/apasl2.gif)
![apasl3.gif](../images/031211/031211-2/apasl3.gif)
![apasl4.gif](../images/031211/031211-2/apasl4.gif)
![apasl5.gif](../images/031211/031211-2/apasl5.gif)
![apasl6.gif](../images/031211/031211-2/apasl6.gif)
![apasl7.gif](../images/031211/031211-2/apasl7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|